[P02BB01, trichlorfon, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Disopyramide.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Disopyramide.]
[J01GA01, streptomycin, Disopyramide may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Fingolimod may increase the arrhythmogenic activities of Disopyramide.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A02BX02, sucralfate, Disopyramide may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Disopyramide may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sulfadiazine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Disopyramide.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AL01, sulpiride, Disopyramide may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glymidine.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Disopyramide.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Disopyramide.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Disopyramide.]
[B01AE07, dabigatran etexilate, Disopyramide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Disopyramide.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Tetrabenazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S03AA02, tetracycline, Disopyramide may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A04AD10, dronabinol, The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Dronabinol.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Disopyramide can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Disopyramide can be decreased when combined with Thiabendazole.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Disopyramide.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01AC01, thiotepa, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Thioridazine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01BB04, aprindine, Disopyramide may increase the arrhythmogenic activities of Aprindine.]
[B02AB01, aprotinin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, Disopyramide may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[B01AC05, ticlopidine, The metabolism of Disopyramide can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tilidine.]
[S01ED01, timolol, Disopyramide may increase the bradycardic activities of Timolol.]
[P01AB02, tinidazole, Disopyramide may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Disopyramide may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tolbutamide.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Disopyramide.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Disopyramide.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Disopyramide is combined with Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Demecarium.]
[A16AX12, trientine, Disopyramide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01AD02, trifluridine, Disopyramide may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Disopyramide.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Disopyramide.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Disopyramide.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Disopyramide is combined with Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Disopyramide.]
[A03AA05, trimebutine, Disopyramide may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Disopyramide may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AC02, trimethadione, Disopyramide may increase the arrhythmogenic activities of Trimethadione.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Disopyramide is combined with Trimethaphan.]
[J01EA01, trimethoprim, Disopyramide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, Trimipramine may decrease the hypoglycemic activities of Disopyramide.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Butylscopolamine.]
[J01FA08, troleandomycin, Troleandomycin may increase the QTc-prolonging activities of Disopyramide.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Disopyramide.]
[L01FX04, ipilimumab, Disopyramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Vandetanib.]
[R02AA14, oxyquinoline, Disopyramide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Disopyramide can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Disopyramide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Disopyramide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Disopyramide.]
[S01AA28, vancomycin, Disopyramide may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[B01AF01, rivaroxaban, Disopyramide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Disopyramide.]
[C08DA01, verapamil, The risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide.]
[N06AX09, viloxazine, The metabolism of Disopyramide can be decreased when combined with Viloxazine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[B01AA03, warfarin, Disopyramide may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Disopyramide can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01EC01, vemurafenib, The serum concentration of Disopyramide can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M05BA05, tiludronic acid, Disopyramide may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Disopyramide may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Disopyramide.]
[A02BC04, rabeprazole, Disopyramide may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Disopyramide may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Disopyramide.]
[L01EJ01, ruxolitinib, Disopyramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Disopyramide.]
[J01DH04, doripenem, Disopyramide may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Disopyramide may increase the bradycardic activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Disopyramide can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Disopyramide can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01FA01, atropine, Disopyramide may increase the arrhythmogenic activities of Atropine.]
[M01CB03, auranofin, Disopyramide may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Disopyramide.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Disopyramide.]
[B03XA04, peginesatide, Disopyramide may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Disopyramide may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Disopyramide.]
[L01BC05, gemcitabine, Disopyramide may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Disopyramide may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Disopyramide.]
[M03BX01, baclofen, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Disopyramide is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Disopyramide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Disopyramide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Disopyramide.]
[L04AA31, teriflunomide, The serum concentration of Disopyramide can be decreased when it is combined with Teriflunomide.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Disopyramide.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01AA01, acetyldigitoxin, Disopyramide may increase the arrhythmogenic activities of Acetyldigitoxin.]
[D02BA02, octinoxate, Disopyramide may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Disopyramide can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Disopyramide.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08CA13, lercanidipine, Disopyramide may increase the arrhythmogenic activities of Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06DA02, donepezil, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Disopyramide is combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Disopyramide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[H01CB05, pasireotide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pasireotide.]
[V08CA11, gadofosveset, Disopyramide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Disopyramide may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Disopyramide.]
[C04AX11, bencyclane, Disopyramide may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Disopyramide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Disopyramide.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Disopyramide.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Disopyramide.]
[A06AX06, tegaserod, The metabolism of Disopyramide can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Disopyramide.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin detemir.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Disopyramide.]
[L03AA12, ancestim, Disopyramide may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The therapeutic efficacy of Disopyramide can be increased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AA18, everolimus, Everolimus may increase the QTc-prolonging activities of Disopyramide.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Disopyramide.]
[L01EC02, dabrafenib, The serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L01EE01, trametinib, Disopyramide may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V09AX05, florbetapir F-18, Disopyramide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08EA02, bepridil, Disopyramide may increase the arrhythmogenic activities of Bepridil.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Lixisenatide.]
[C02KX04, macitentan, Disopyramide may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G03AC08, etonogestrel, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Etonogestrel.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AP05, simeprevir, The metabolism of Disopyramide can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Disopyramide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Disopyramide.]
[C01CA27, droxidopa, Disopyramide may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, Disopyramide may increase the bradycardic activities of Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A16AA07, metreleptin, The metabolism of Disopyramide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Disopyramide can be increased when combined with Apremilast.]
[L02BG02, formestane, Disopyramide may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Disopyramide.]
[S01ED02, betaxolol, Disopyramide may increase the bradycardic activities of Betaxolol.]
[V03AB34, fomepizole, Disopyramide may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Disopyramide.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Disopyramide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Disopyramide.]
[A03BA03, hyoscyamine, Disopyramide may increase the arrhythmogenic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Disopyramide.]
[L01XH04, belinostat, The metabolism of Disopyramide can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Disopyramide.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Disopyramide.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Disopyramide is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A16AX10, eliglustat, The risk or severity of Cardiac Arrhythmia can be increased when Eliglustat is combined with Disopyramide.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V04CX03, methacholine, Disopyramide may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Disopyramide.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Disopyramide is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Disopyramide is combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Disopyramide.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Disopyramide.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Disopyramide.]
[B01AF03, edoxaban, Disopyramide may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AC10, secukinumab, The metabolism of Disopyramide can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Disopyramide.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Disopyramide.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Disopyramide.]
[L01DC01, bleomycin, Disopyramide may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Disopyramide is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Disopyramide.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Acarbose.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin degludec.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V03AB37, idarucizumab, Disopyramide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The metabolism of Disopyramide can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Disopyramide can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Disopyramide.]
[L01XG03, ixazomib, Disopyramide may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Disopyramide.]
[M04AB05, lesinurad, Disopyramide may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Disopyramide.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01XX52, venetoclax, The metabolism of Disopyramide can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A02AD05, aluminum magnesium silicate, Disopyramide may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Disopyramide.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Disopyramide.]
[C08CA01, amlodipine, Disopyramide may increase the arrhythmogenic activities of Amlodipine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A05AA04, obeticholic acid, The metabolism of Disopyramide can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C07AA19, bupranolol, Disopyramide may increase the bradycardic activities of Bupranolol.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Artemether.]
[M02AA03, clofezone, Disopyramide may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Disopyramide is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Disopyramide.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01XK03, rucaparib, The metabolism of Disopyramide can be increased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Disopyramide.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Disopyramide.]
[L01EF02, ribociclib, The metabolism of Disopyramide can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Disopyramide.]
[R03CC12, bambuterol, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Bambuterol.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Disopyramide.]
[A06AH05, naldemedine, Disopyramide may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Deutetrabenazine.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BC01, caffeine, The metabolism of Disopyramide can be decreased when combined with Caffeine.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Disopyramide.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Benfluorex.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P01CA02, benznidazole, Disopyramide may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Disopyramide.]
[J05AF06, abacavir, Disopyramide may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Disopyramide can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Disopyramide may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Disopyramide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Disopyramide can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01MA23, delafloxacin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Delafloxacin.]
[P03AC02, bioallethrin, Disopyramide may increase the arrhythmogenic activities of Bioallethrin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Acetylcholine.]
[L01BC06, capecitabine, Disopyramide may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Disopyramide can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Disopyramide can be increased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Disopyramide can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C07AA17, bopindolol, Disopyramide may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Disopyramide.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Disopyramide.]
[C01AA02, acetyldigoxins, Disopyramide may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Semaglutide.]
[N01BX04, capsaicin, The metabolism of Disopyramide can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Ertugliflozin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Disopyramide.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Disopyramide.]
[L02BB05, apalutamide, The metabolism of Disopyramide can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Disopyramide can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Disopyramide.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Disopyramide.]
[L03AB06, interferon alfa-n1, The metabolism of Disopyramide can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Disopyramide may increase the bradycardic activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Cannabidiol.]
[L04AA37, baricitinib, Disopyramide may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Disopyramide.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Disopyramide.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01GB14, plazomicin, Disopyramide may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Disopyramide may increase the bradycardic activities of Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ivosidenib.]
[A16AX14, migalastat, Disopyramide may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Disopyramide can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Carbutamide.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D08AE05, chloroxylenol, Disopyramide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Disopyramide.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Disopyramide.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Disopyramide is combined with Revefenacin.]
[L04AA39, emapalumab, The metabolism of Disopyramide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Disopyramide can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Disopyramide.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Disopyramide.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Disopyramide.]
[C01BG07, cifenline, Disopyramide may increase the arrhythmogenic activities of Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Disopyramide.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01ED05, carteolol, Disopyramide may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Disopyramide.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01FA09, clarithromycin, Clarithromycin may increase the QTc-prolonging activities of Disopyramide.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Disopyramide.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Disopyramide.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Disopyramide.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Disopyramide.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Disopyramide.]
[L04AB01, etanercept, The metabolism of Disopyramide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Disopyramide.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C03BX03, cicletanine, Disopyramide may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Disopyramide can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Disopyramide.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Disopyramide.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Disopyramide.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Disopyramide.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G03AC09, desogestrel, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Disopyramide can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Disopyramide can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Disopyramide may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Disopyramide.]
[S01XA12, dexpanthenol, Disopyramide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AA53, teprotumumab, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Teprotumumab.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AX21, diacetylrhein, The metabolism of Disopyramide can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Disopyramide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Disopyramide can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Disopyramide.]
[R02AA03, dichlorobenzyl alcohol, Disopyramide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Dienogest.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Disopyramide.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AH02, rofecoxib, The metabolism of Disopyramide can be decreased when combined with Rofecoxib.]
[C08CA16, clevidipine, Disopyramide may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Disopyramide may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01FA13, dirithromycin, Dirithromycin may increase the QTc-prolonging activities of Disopyramide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Disopyramide.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Disopyramide.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Disopyramide can be decreased when combined with Capmatinib.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Disopyramide.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Disopyramide.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[V08CA05, mangafodipir, Disopyramide may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Disopyramide.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Disopyramide.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Disopyramide.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Disopyramide.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AC19, satralizumab, The serum concentration of Disopyramide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Disopyramide is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Disopyramide.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Disopyramide.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Disopyramide.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Disopyramide.]
[N06BX18, vinpocetine, Disopyramide may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Disopyramide.]
[A16AX20, lonafarnib, The metabolism of Disopyramide can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Disopyramide may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Disopyramide.]
[M01AX25, chondroitin sulfates, Disopyramide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Disopyramide can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Disopyramide can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Disopyramide.]
[C01CA19, fenoldopam, Disopyramide may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Fenozolone.]
[J01DD15, cefdinir, Disopyramide may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Disopyramide.]
[N02BG07, flupirtine, Disopyramide may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Disopyramide.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Disopyramide.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Disopyramide can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V08CA04, gadoteridol, Disopyramide may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, Disopyramide may increase the arrhythmogenic activities of Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Disopyramide.]
[L01XX73, sotorasib, The serum concentration of Disopyramide can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Disopyramide.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Disopyramide.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Disopyramide.]
[H01AC07, somapacitan, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Disopyramide is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Disopyramide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Disopyramide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Disopyramide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Clemastine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Disopyramide.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Clenbuterol.]
[J01FF01, clindamycin, Clindamycin may increase the QTc-prolonging activities of Disopyramide.]
[N06AX25, St. John's wort extract, The metabolism of Disopyramide can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Disopyramide can be decreased when combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Disopyramide.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Disopyramide.]
[B06AX04, mitapivat, The therapeutic efficacy of Disopyramide can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Disopyramide.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Disopyramide.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01EA04, clonidine, Clonidine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01EB24, mavacamten, The serum concentration of Disopyramide can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Clopamide.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Disopyramide.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Disopyramide.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Disopyramide.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sotagliflozin.]
[J01GB12, arbekacin, Disopyramide may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Disopyramide.]
[H01AC08, somatrogon, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Disopyramide can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M04AC01, colchicine, Disopyramide may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Disopyramide is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Homatropine.]
[J01XB01, colistin, Disopyramide may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L04AA13, leflunomide, The serum concentration of Disopyramide can be decreased when it is combined with Leflunomide.]
[C01BA13, hydroquinidine, Disopyramide may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A04AA03, tropisetron, Disopyramide may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin glargine.]
[J01FA15, telithromycin, Telithromycin may increase the QTc-prolonging activities of Disopyramide.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Disopyramide.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Disopyramide.]
[J05AB14, valganciclovir, Disopyramide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Disopyramide may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Disopyramide may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Disopyramide may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Disopyramide may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Disopyramide may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Disopyramide can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Disopyramide.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Disopyramide.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Disopyramide can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Disopyramide may increase the arrhythmogenic activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Disopyramide.]
[N03AX09, lamotrigine, Disopyramide may increase the arrhythmogenic activities of Lamotrigine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Disopyramide.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Disopyramide.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Disopyramide.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R06AX13, loratadine, Disopyramide may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C09AA03, lisinopril, Disopyramide may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Disopyramide.]
[C08CA11, manidipine, Disopyramide may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Disopyramide.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Mefenorex.]
[C07AA14, mepindolol, Disopyramide may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Disopyramide.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Disopyramide.]
[J01DH02, meropenem, Disopyramide may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, Disopyramide may increase the arrhythmogenic activities of Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Disopyramide is combined with Metixene.]
[C04AX01, cyclandelate, Disopyramide may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Disopyramide may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, Midecamycin may increase the QTc-prolonging activities of Disopyramide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Miglitol.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Disopyramide is combined with Cyclopentolate.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01XA18, cyclosporine, The metabolism of Disopyramide can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BA07, modafinil, The metabolism of Disopyramide can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Disopyramide.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Disopyramide can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Disopyramide.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Disopyramide.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Disopyramide.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Disopyramide.]
[G03XA01, danazol, The metabolism of Disopyramide can be decreased when combined with Danazol.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Disopyramide.]
[N07BB05, nalmefene, Disopyramide may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C07AB12, nebivolol, Disopyramide may increase the bradycardic activities of Nebivolol.]
[S01GX04, nedocromil, Disopyramide may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Disopyramide can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01DX16, nicorandil, Disopyramide may increase the arrhythmogenic activities of Nicorandil.]
[L02BB02, nilutamide, Disopyramide may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Disopyramide.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Normethadone.]
[B01AX05, fondaparinux, Disopyramide may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Disopyramide.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Disopyramide.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Disopyramide.]
[C01AA07, deslanoside, Disopyramide may increase the arrhythmogenic activities of Deslanoside.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Disopyramide.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Disopyramide.]
[V04CH02, indigo carmine, Disopyramide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Disopyramide.]
[J01DH03, ertapenem, Disopyramide may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Disopyramide.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Disopyramide.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Disopyramide.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Disopyramide can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dextromoramide.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Disopyramide.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Disopyramide is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Disopyramide.]
[P03AC04, permethrin, Disopyramide may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V03AH01, diazoxide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Diazoxide.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Disopyramide.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R05DA08, pholcodine, Disopyramide may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Disopyramide.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Disopyramide.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dicyclomine.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Disopyramide can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Disopyramide may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, Disopyramide may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Pioglitazone.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Disopyramide is combined with Pipenzolate.]
[L01DC04, ixabepilone, Ixabepilone may increase the QTc-prolonging activities of Disopyramide.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Erlotinib.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Pirbuterol.]
[C03CA03, piretanide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Piretanide.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Disopyramide.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Disopyramide.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Poldine.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Disopyramide.]
[C01AA04, digitoxin, Disopyramide may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, Disopyramide may increase the arrhythmogenic activities of Digoxin.]
[C02DB01, dihydralazine, The metabolism of Disopyramide can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Hydromorphone.]
[L04AX04, lenalidomide, Disopyramide may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Disopyramide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Disopyramide.]
[H03BC01, potassium perchlorate, Disopyramide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Disopyramide may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Disopyramide.]
[C08DB01, diltiazem, Disopyramide may increase the arrhythmogenic activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Disopyramide.]
[V03AB09, dimercaprol, Disopyramide may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Disopyramide may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Disopyramide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Disopyramide.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Disopyramide is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Disopyramide.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Cisapride.]
[S01XA23, sirolimus, Sirolimus may increase the QTc-prolonging activities of Disopyramide.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Reproterol.]
[S01AX06, resorcinol, Disopyramide may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Disopyramide can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Disopyramide can be increased when used in combination with Pipemidic acid.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Disopyramide.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Disopyramide.]
[C01DA05, pentaerythritol tetranitrate, Disopyramide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[N07AA03, distigmine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Disopyramide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Disopyramide can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01MB01, rosoxacin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Disopyramide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disopyramide.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Disopyramide may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Disopyramide.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Disopyramide.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C01CA07, dobutamine, Disopyramide may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Disopyramide.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Disopyramide.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Disopyramide.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Disopyramide.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Disopyramide.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Disopyramide.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Disopyramide.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Disopyramide.]
[R03DA01, dyphylline, Disopyramide may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Disopyramide can be increased when used in combination with Succinylsulfathiazole.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Disopyramide.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V04CX07, edrophonium, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, Disopyramide may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Disopyramide.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Temafloxacin.]
[L01AX03, temozolomide, Disopyramide may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Disopyramide.]
[G04BD05, terodiline, Disopyramide may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Disopyramide may increase the bradycardic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Disopyramide.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Disopyramide.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Disopyramide is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Toremifene.]
[C03CA04, torsemide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Torasemide.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Disopyramide.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L02AE04, triptorelin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Triptorelin.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01MA04, enoxacin, The metabolism of Disopyramide can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Xamoterol.]
[S01GA03, xylometazoline, Disopyramide may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Disopyramide may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Epinephrine.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N03AX15, zonisamide, Disopyramide may increase the arrhythmogenic activities of Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin glulisine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01BG01, moricizine, Disopyramide may increase the arrhythmogenic activities of Moricizine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02CA02, ergotamine, The metabolism of Disopyramide can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Disopyramide may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, Erythromycin may increase the QTc-prolonging activities of Disopyramide.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Disopyramide.]
[G03CA03, estradiol, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Disopyramide.]
[J04AK02, ethambutol, Disopyramide may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Disopyramide.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Disopyramide.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Disopyramide.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Ethinylestradiol.]
[C01BD05, ibutilide, Disopyramide may increase the arrhythmogenic activities of Ibutilide.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Profenamine.]
[N03AD01, ethosuximide, Disopyramide may increase the arrhythmogenic activities of Ethosuximide.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Disopyramide.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01BA05, ajmaline, Disopyramide may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tacrolimus.]
[A02BA04, nizatidine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Disopyramide can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Disopyramide may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AB08, fluvoxamine, The metabolism of Disopyramide can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Disopyramide may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Disopyramide may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide.]
[M01CB01, gold sodium thiomalate, Disopyramide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Disopyramide may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Disopyramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Disopyramide.]
[A16AA01, levocarnitine, Disopyramide may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Disopyramide can be increased when combined with Albendazole.]
[C08CA02, felodipine, Disopyramide may increase the arrhythmogenic activities of Felodipine.]
[C08EA01, fendiline, Disopyramide may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Disopyramide is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Disopyramide is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Disopyramide.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Disopyramide.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Disopyramide is combined with Flavoxate.]
[C01BC04, flecainide, Disopyramide may increase the arrhythmogenic activities of Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Fluconazole.]
[J02AX01, flucytosine, Disopyramide may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Disopyramide.]
[V03AB25, flumazenil, Disopyramide may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Disopyramide.]
[N07CA03, flunarizine, Disopyramide may increase the arrhythmogenic activities of Flunarizine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Disopyramide.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Disopyramide.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Disopyramide.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01BC09, floxuridine, Disopyramide may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Disopyramide.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Disopyramide.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Disopyramide.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Disopyramide.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Flupentixol.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Disopyramide.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AG01, fluspirilene, Disopyramide may increase the arrhythmogenic activities of Fluspirilene.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Disopyramide.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S02AA17, fosfomycin, Disopyramide may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Disopyramide.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AE10, darunavir, The metabolism of Disopyramide can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Disopyramide.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08DA02, gallopamil, Disopyramide may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Disopyramide is combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C10AB04, gemfibrozil, The metabolism of Disopyramide can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Disopyramide.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Disopyramide.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Disopyramide.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Disopyramide.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Liraglutide.]
[N03AD03, methsuximide, Disopyramide may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Disopyramide is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Disopyramide.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glipizide.]
[H04AA01, glucagon, Disopyramide may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Disopyramide.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Disopyramide.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Disopyramide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Disopyramide.]
[C07AB09, esmolol, Disopyramide may increase the bradycardic activities of Esmolol.]
[M01CB04, aurothioglucose, Disopyramide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Disopyramide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Disopyramide may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Disopyramide may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Disopyramide.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Disopyramide.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Haloperidol.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L02AE05, histrelin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Disopyramide.]
[N06BX13, idebenone, Disopyramide may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin aspart.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M04AA01, allopurinol, Disopyramide may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, Disopyramide may increase the arrhythmogenic activities of Losartan.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Disopyramide.]
[G03DC01, allylestrenol, Disopyramide may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Disopyramide.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Disopyramide.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Disopyramide can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Disopyramide may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Disopyramide may increase the arrhythmogenic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Disopyramide.]
[C09AA04, perindopril, Disopyramide may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Disopyramide may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Disopyramide.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Disopyramide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Disopyramide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[B05AA07, hetastarch, Disopyramide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Disopyramide.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[B05XA08, sodium acetate, Disopyramide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Disopyramide.]
[L01AA06, ifosfamide, Disopyramide may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Disopyramide.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Disopyramide is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Disopyramide.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Disopyramide.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Disopyramide.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01CE01, topotecan, Disopyramide may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Disopyramide.]
[A11HA07, inositol, Disopyramide may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Disopyramide is combined with Piperidolate.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Disopyramide.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sitagliptin.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Disopyramide.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Disopyramide.]
[C07AA01, alprenolol, Disopyramide may increase the bradycardic activities of Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Quinethazone.]
[L03AB09, interferon alfacon-1, The metabolism of Disopyramide can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, Disopyramide may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Disopyramide.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Disopyramide.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Disopyramide.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01EB07, isoflurophate, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J04AC01, isoniazid, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Disopyramide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Exenatide.]
[D10BA01, isotretinoin, Disopyramide may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Isoxsuprine.]
[J01FA07, josamycin, Josamycin may increase the QTc-prolonging activities of Disopyramide.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01AA24, kanamycin, Disopyramide may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Disopyramide.]
[L04AC07, tocilizumab, The metabolism of Disopyramide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[B01AC22, prasugrel, Disopyramide may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Disopyramide can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[V03AC03, deferasirox, The serum concentration of Disopyramide can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Disopyramide can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Disopyramide.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Arbutamine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Disopyramide.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Disopyramide.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C07AG01, labetalol, Disopyramide may increase the bradycardic activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Disopyramide.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Disopyramide.]
[N07AA30, ambenonium, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Disopyramide.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Disopyramide.]
[S02DA01, lidocaine, Disopyramide may increase the arrhythmogenic activities of Lidocaine.]
[C08EX01, lidoflazine, Disopyramide may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, Disopyramide may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Disopyramide can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Disopyramide.]
[A07DA03, loperamide, Disopyramide may increase the arrhythmogenic activities of Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C10AA02, lovastatin, The metabolism of Disopyramide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01EG01, temsirolimus, Temsirolimus may increase the QTc-prolonging activities of Disopyramide.]
[B05XA11, magnesium chloride, Disopyramide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Disopyramide.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Disopyramide.]
[V04CC02, magnesium sulfate, Disopyramide may increase the arrhythmogenic activities of Magnesium sulfate.]
[L01BA05, pralatrexate, Disopyramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Disopyramide can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01AA08, medigoxin, Disopyramide may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Disopyramide.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Disopyramide.]
[C03BA05, mefruside, The therapeutic efficacy of Disopyramide can be increased when used in combination with Mefruside.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Disopyramide.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Disopyramide is combined with Meptazinol.]
[G04BX16, tiopronin, Disopyramide may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Disopyramide.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Disopyramide.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Metaraminol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Disopyramide.]
[H01CB03, lanreotide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Disopyramide is combined with Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Disopyramide.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01EC05, methazolamide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Methazolamide.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[H03BB02, methimazole, The metabolism of Disopyramide can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Disopyramide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N02BG08, ziconotide, Disopyramide may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Methoxamine.]
[D05BA02, methoxsalen, The metabolism of Disopyramide can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Disopyramide.]
[C02AB01, methyldopa, Disopyramide may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Disopyramide.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Disopyramide.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Disopyramide.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Disopyramide.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Disopyramide.]
[C03BA08, metolazone, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, Disopyramide may increase the bradycardic activities of Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Disopyramide.]
[V04CD01, metyrapone, Disopyramide may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, Disopyramide may increase the arrhythmogenic activities of Mexiletine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Disopyramide.]
[S02AA13, miconazole, The metabolism of Disopyramide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Disopyramide.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Disopyramide.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Disopyramide.]
[J05AH01, zanamivir, Disopyramide may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[J01FA11, miocamycin, Miocamycin may increase the QTc-prolonging activities of Disopyramide.]
[L01XX23, mitotane, The metabolism of Disopyramide can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C01BD01, amiodarone, Amiodarone may increase the QTc-prolonging activities of Disopyramide.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Disopyramide.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Disopyramide can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Disopyramide.]
[G04BA01, ammonium chloride, Disopyramide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Disopyramide.]
[L04AA06, mycophenolic acid, Disopyramide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Disopyramide.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Disopyramide.]
[N03AB05, fosphenytoin, The serum concentration of Disopyramide can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Disopyramide can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, Disopyramide may increase the bradycardic activities of Nadolol.]
[J01CA04, amoxicillin, Disopyramide may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[J01CF06, nafcillin, The metabolism of Disopyramide can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Disopyramide can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Disopyramide can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Disopyramide.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Naphazoline.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Disopyramide.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S03AA01, neomycin, Disopyramide may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Disopyramide is combined with Remifentanil.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Repaglinide.]
[C01CX08, levosimendan, Disopyramide may increase the arrhythmogenic activities of Levosimendan.]
[B01AC17, tirofiban, Disopyramide may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[S01EB06, neostigmine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S01AA19, ampicillin, Disopyramide may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Disopyramide may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Disopyramide may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C01CE01, inamrinone, Disopyramide may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08CA04, nicardipine, Disopyramide may increase the arrhythmogenic activities of Nicardipine.]
[P02DA01, niclosamide, The metabolism of Disopyramide can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Disopyramide.]
[C08CA05, nifedipine, Disopyramide may increase the arrhythmogenic activities of Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C08CA06, nimodipine, Disopyramide may increase the arrhythmogenic activities of Nimodipine.]
[C08CA07, nisoldipine, Disopyramide may increase the arrhythmogenic activities of Nisoldipine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08CA08, nitrendipine, Disopyramide may increase the arrhythmogenic activities of Nitrendipine.]
[R07AX01, nitric oxide, Disopyramide may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Disopyramide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Disopyramide.]
[C02DD01, nitroprusside, Disopyramide may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Disopyramide.]
[G03DC02, norethindrone, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Disopyramide can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the hypoglycemic activities of Disopyramide.]
[L03AB07, interferon beta-1a, The metabolism of Disopyramide can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, Disopyramide may increase the arrhythmogenic activities of Nylidrin.]
[H01CB02, octreotide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Disopyramide.]
[J01FA05, oleandomycin, Oleandomycin may increase the QTc-prolonging activities of Disopyramide.]
[L04AC04, rilonacept, The metabolism of Disopyramide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Disopyramide can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Disopyramide.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Disopyramide is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Orciprenaline.]
[G04CA02, tamsulosin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Disopyramide may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Disopyramide.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Disopyramide can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, Disopyramide may increase the bradycardic activities of Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Oxymetazoline.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Disopyramide.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Disopyramide.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Disopyramide.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Asenapine.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tapentadol.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J04AB30, capreomycin, Disopyramide may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Disopyramide.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Disopyramide.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01MA03, pefloxacin, The therapeutic efficacy of Disopyramide can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Fesoterodine.]
[C07AA23, penbutolol, Disopyramide may increase the bradycardic activities of Penbutolol.]
[N05AG03, penfluridol, Disopyramide may increase the arrhythmogenic activities of Penfluridol.]
[J01CE09, penicillin G procaine, Disopyramide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Disopyramide can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Disopyramide may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Disopyramide.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C08EX02, perhexiline, Disopyramide may increase the arrhythmogenic activities of Perhexiline.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Disopyramide.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Disopyramide.]
[N03AA02, phenobarbital, The metabolism of Disopyramide can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Disopyramide.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Phenoperidine.]
[A08AA01, phentermine, The therapeutic efficacy of Disopyramide can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Disopyramide may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S01GA05, phenylephrine, The metabolism of Disopyramide can be increased when combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Disopyramide can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Disopyramide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Disopyramide.]
[V03AB19, physostigmine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Physostigmine.]
[B02BA01, vitamin K1, Disopyramide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[C08CX01, mibefradil, Disopyramide may increase the arrhythmogenic activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Pimozide.]
[C07AA03, pindolol, Disopyramide may increase the bradycardic activities of Pindolol.]
[J01CA12, piperacillin, Disopyramide may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Disopyramide can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N06BX03, piracetam, Disopyramide may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Grepafloxacin.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AG02, delavirdine, The metabolism of Disopyramide can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AC08, canakinumab, The metabolism of Disopyramide can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Disopyramide can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Saxagliptin.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Disopyramide is combined with Potassium chloride.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin lispro.]
[C07AB01, practolol, Disopyramide may increase the bradycardic activities of Practolol.]
[C01BA08, prajmaline, Disopyramide may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Disopyramide.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Disopyramide.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Disopyramide.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Disopyramide.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Disopyramide.]
[C01DX02, prenylamine, Disopyramide may increase the arrhythmogenic activities of Prenylamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Disopyramide.]
[N03AA03, primidone, The metabolism of Disopyramide can be increased when combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Disopyramide can be increased when used in combination with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Disopyramide.]
[C01BA02, procainamide, Disopyramide may increase the arrhythmogenic activities of Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C10AB05, fenofibrate, Disopyramide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Disopyramide.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Procyclidine.]
[G03DA04, progesterone, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Disopyramide.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Disopyramide.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Disopyramide is combined with Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Romidepsin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Disopyramide is combined with Dextropropoxyphene.]
[C07AA05, propranolol, Disopyramide may increase the bradycardic activities of Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[B01AC09, epoprostenol, Disopyramide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Disopyramide.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Disopyramide.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Disopyramide is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Disopyramide is combined with Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J04AK01, pyrazinamide, Disopyramide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[C01BA01, quinidine, Disopyramide may increase the arrhythmogenic activities of Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Disopyramide.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Disopyramide.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J05AP01, ribavirin, Disopyramide may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Disopyramide can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Disopyramide.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Disopyramide.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Disopyramide.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Disopyramide.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[J01GB08, sisomicin, Disopyramide may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Disopyramide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Disopyramide.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Disopyramide.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Disopyramide.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Disopyramide.]
[C01DA14, isosorbide mononitrate, Disopyramide may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Disopyramide can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Disopyramide may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Ipratropium.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
